OraSure Technologies Inc
Change company Symbol lookup
Select an option...
OSUR OraSure Technologies Inc
MCBC Macatawa Bank Corp
LCAAU L Catterton Asia Acquisition Corp
SBUX Starbucks Corp
MRDY Mobile Ready Entertainment Corp
MANT ManTech International Corp
LXFR Luxfer Holdings PLC
SYZLF Sylogist Ltd
BSX Boston Scientific Corp
PNGAY Ping An Insurance Group Co of China Ltd
Go

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.

Price
Delayed
$10.98
Day's Change
0.415 (3.93%)
Bid
--
Ask
--
B/A Size
--
Day's High
11.06
Day's Low
10.60
Volume
(Light)

Today's volume of 107,843 shares is on pace to be much lighter than OSUR's 10-day average volume of 1,337,196 shares.

107,843

Integral Molecular's Rapid SARS-CoV-2 Epitope Mapping Supports Regulatory Requirements for the Development of Therapeutic Antibodies Effective Against Viral Variants

10:24 am ET June 11, 2021 (PR Newswire) Print

At the forefront of the fight against COVID-19, Integral Molecular's rapid Epitope Mapping technology is being used to pinpoint precise binding sites of therapeutic SARS-CoV-2 antibodies under development and can help determine their effectiveness against emerging viral variants. These efforts are important in keeping pace with the ever-changing virus and the requirements of regulatory agencies such as the FDA in testing new therapeutics against the virus.

https://mma.prnewswire.com/media/792952/Integral_Molecular_Logo.jpg

Using its Shotgun Mutagenesis Epitope Mapping technology, Integral Molecular identifies the specific amino acids bound by antibodies on all regions of the Spike protein, including the receptor binding domain (RBD), N-terminal domain (NTD) and S2 regions. In most cases, complex conformational epitopes can be mapped in 4 weeks. Integral Molecular can also assess an individual antibody's binding to Spike variants of greatest concern, including UK B.1.1.7 (Alpha), South African B.1.351 (Beta), Brazilian P.1 (Gamma), and Indian B.1.617.2 (Delta) variants.

"As emerging variants continue to devastate much of the world, it is important to remain vigilant with therapeutics that are effective against the evolving virus," said Edgar Davidson, PhD, Virologist at Integral Molecular. "We are proud to support scientists in their FDA filings, providing data quickly to better understand their antibodies' mechanisms of action and potential for viral resistance."

Epitopes mapped by Integral Molecular have been essential in studies examining how antibodies fight COVID-19. These include characterization of NTD-targeting antibodies that provided prophylactic or therapeutic protection in animals (Suryadevara et al., Cell, 2021), development of a cocktail of anti-RBD antibodies resistant to viral escape when used in combination (Ku et al., Nature Communications, 2021), and identification of commonly occurring antibodies in the population that target Spike regions including S2 (Chen et al., bioRxiv, 2021). In addition to epitope mapping, Integral Molecular offers pseudotyped SARS-CoV-2 reporter virus particles to test antibody neutralization against over 30 reference strains and emerging variants.

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in discovering and characterizing therapeutic antibodies against membrane proteins, an important group of drug targets found on the surfaces of cells and viruses. Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Press Contact: Integral Molecular, Inc. Soma Banik, PhD, Director of Communications 215-966-6061 info@integralmolecular.com www.integralmolecular.com

https://c212.net/c/img/favicon.png?sn=PH08612&sd=2021-06-11

View original content to download multimedia:http://www.prnewswire.com/news-releases/integral-moleculars-rapid-sars-cov-2-epitope-mapping-supports-regulatory-requirements-for-the-development-of-therapeutic-antibodies-effective-against-viral-variants-301310902.html

SOURCE Integral Molecular

https://rt.prnewswire.com/rt.gif?NewsItemId=PH08612&Transmission_Id=202106111023PR_NEWS_USPR_____PH08612&DateId=20210611

comtex tracking

COMTEX_388143206/1005/2021-06-11T10:24:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.